Moderna’s stock buoyed by positive data in trial of melanoma treatment

The companies said that after about three years, the combination reduced the risk of recurrence or death by 49% in a Phase 2 trial and the risk of distant metastasis or death by 62%, as compared with Keytruda alone.

“As we continue to follow participants in the Keynote-942/mRNA-4157-P201 study, we are excited to see such a robust clinical benefit with mRNA-4157 (V940) as adjuvant treatment in combination with Keytruda in people with resected high-risk melanoma,” said Kyle Holen, senior vice president and head of development in therapeutics and oncology at Moderna.

“These data add another positive analysis to the multiple endpoints and subgroups previously assessed in this study,” he said.

See now: Moderna reorganizes to sharpen focus on vaccine sales, chief commercial officer to leave company

Adverse events were consistent with previous trials and were primarily fatigue, injection-site pain and chills.

The companies have started Phase 3 trials of mRNA-4157 in combination with Keytruda, which has been granted breakthrough designation by the U.S. Food and Drug Administration and by the European Medicines Agency, the European regulator.

Moderna and Merck presented data on the primary endpoint in April at the annual meeting of the American Association for Cancer Research. In June, they presented data on the study’s secondary endpoint at the annual meeting of the American Society of Clinical Oncology. Data from the primary analysis has been submitted for publication in a peer-reviewed journal, they said in a statement.

Read now: Moderna posts wider-than-expected loss, reins in full-year outlook 

Merck’s stock
MRK,
-0.36%
was down 1.4% in Thursday morning trading and is down 5% to date in 2023. Moderna’s stock has fallen 50% year to date, while the S&P 500
SPX,
+0.26%
has gained 22.6%.